Dr. Pedram Fadavi | Radiation oncology | Best Researcher Award
Dr. Pedram Fadavi, M.D., is a distinguished radiation oncologist and associate professor at Iran University of Medical Sciences (IUMS). Born in Tehran, Iran (1974), he specializes in cancer treatment, radiotherapy, and oncological research. With over two decades of experience, he has contributed extensively to academia and clinical practice. His expertise spans breast, head, neck, and gynecologic cancers. He has published influential research in radiomics, chemotherapy delays, and treatment-induced complications. A dedicated educator, he mentors medical students and residents while advancing oncology research. 📚💡
Profile
Education 🎓
Dr. Fadavi earned his M.D. (2000) and board certification in Radiation Oncology (2006) from Shahid Beheshti University, Tehran. He completed a seven-year medical program (1993-2000) and specialized in radiation oncology during his residency (2002-2006). He holds an Iran Medical Council license (No. 76602) and actively contributes to medical education and research at IUMS. His training provided a strong foundation in oncologic treatments and innovative radiotherapy techniques. 🔬📖
Experience 👨🏫
Since 2006, Dr. Fadavi has served as a radiation oncologist at Haftome Tir Hospital (IUMS). He became an associate professor in 2008, teaching at IUMS and Tehran University of Medical Sciences (2011-2013). His clinical expertise includes radiotherapy advancements, cancer management, and interdisciplinary oncology research. He has led multiple projects addressing radiation-induced complications and patient outcomes. His leadership in academic and clinical oncology has shaped the future of radiation therapy in Iran. 🌍🔬
Research Interests 🔬
Dr. Fadavi has received numerous accolades for his contributions to radiation oncology and medical research. His work on radiomics, treatment toxicity, and innovative oncological therapies has been recognized in national and international forums. His publications in leading journals and collaborations with top researchers underscore his impact on global cancer research. He has also been honored for his excellence in medical education, research innovation, and commitment to improving patient care. 📜🏅
Publications 📚
- Prognostic value of promoter hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer
A Ameri, A Alidoosti, Y Hosseini, M Parvin, MH Emranpour, F Taslimi, …Chinese Journal of Cancer Research 23, 306-311
- Magnetic resonance imaging-based target volume delineation in radiation therapy treatment planning for brain tumors using localized region-based active contour
H Aslian, M Sadeghi, SR Mahdavi, FB Mofrad, M Astarakee, N Khaledi, …International Journal of Radiation Oncology* Biology* Physics 87 (1), 195-201
- Short-term cohort study on sensorineural hearing changes in head and neck radiotherapy
S Cheraghi, P Nikoofar, P Fadavi, M Bakhshandeh, S Khoie, …Medical Oncology 32, 1-7
- Allelic distribution of human leukocyte antigen in Iranian patients with pulmonary tuberculosis
H Mahmoudzadeh-Niknam, G Khalili, P FadaviHuman immunology 64 (1), 124-129
- Review on the oncology practice in the midst of COVID-19 crisis: the challenges and solutions
P Fadavi, M Houshyari, ASY Kashi, AM Jarrahi, F Roshanmehr, …Asian Pacific Journal of Cancer Prevention: APJCP 22 (1), 19
- Endorectal ultrasound radiomics in locally advanced rectal cancer patients: despeckling and radiotherapy response prediction using machine learning
S Abbaspour, H Abdollahi, H Arabalibeik, M Barahman, AM Arefpour, …Abdominal Radiology 47 (11), 3645-3659
- Evaluating the effectiveness of combined radiotherapy and hyperthermia for the treatment response of patients with painful bony metastases: A phase 2 clinical trial
T Ariyafar, SR Mahdavi, G Geraily, P Fadavi, B Farhood, M Najafi, …Journal of thermal biology 84, 129-135
- Epstein-barr virus may not be associated with breast cancer in Iranian patients
P Fadavi, M Rostamian, A Arashkia, B Shafaghi, HM NiknamOncol Discov 1 (3)